Roche has completed its $4.3 billion acquisition of Spark Therapeutics, Inc. following the receipt of regulatory approval from all government authorities required by the merger agreement. Severin Schwan, chief executive officer of Roche, said, “We are excited about this important milestone because we believe that together, Roche and Spark will be able to significantly improve the lives of patients through innovative gene therapies. This acquisition supports our long-lasting commitment to brin...